{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:14:02Z","timestamp":1794334442238,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04844-x","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:36:58Z","timestamp":1771378618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in uric acid levels and estimated glomerular filtration rate slope after treatment with dotinurad in patients with hyperuricemia"],"prefix":"10.1186","volume":"27","author":[{"given":"Tatsuya","family":"Mizoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Yamabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"4844_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811\u20139. https:\/\/doi.org\/10.1056\/NEJMra0800885.","journal-title":"N Engl J Med"},{"key":"4844_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, S\u00e1nchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transpl. 2013;28:2221\u20138. https:\/\/doi.org\/10.1093\/ndt\/gft029.","journal-title":"Nephrol Dial Transpl"},{"key":"4844_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","volume":"69","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A, Bjornstad P, Jensen T, Sato Y, Milagres T, Garcia G, Ohno M, Lanaspa MA, Johnson RJ. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69:1036\u201344. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08998.","journal-title":"Hypertension"},{"key":"4844_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12986-021-00618-4","volume":"18","author":"N Wu","year":"2021","unstructured":"Wu N, Xia J, Chen S, Yu C, Xu Y, Xu C, Yan T, Li N, Liu Y, Pan XF. Serum uric acid and risk of incident chronic kidney disease: a National cohort study and updated meta-analysis. Nutr Metab (Lond). 2021;18:94. https:\/\/doi.org\/10.1186\/s12986-021-00618-4.","journal-title":"Nutr Metab (Lond)"},{"key":"4844_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382:2504\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1915833.","journal-title":"N Engl J Med"},{"key":"4844_CR6","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M. Serum urate Lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382:2493\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa1916624.","journal-title":"N Engl J Med"},{"key":"4844_CR7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Febuxostat for cerebral and cardio-renovascular events prevention study. Eur Heart J. 2019;40:1778\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehz119.","journal-title":"Eur Heart J"},{"key":"4844_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447\u201352. https:\/\/doi.org\/10.1038\/nature742.","journal-title":"Nature"},{"issue":"Suppl 1","key":"4844_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol. 2020;24(Suppl 1):53\u201361. https:\/\/doi.org\/10.1007\/s10157-019-01818-2.","journal-title":"Clin Exp Nephrol"},{"key":"4844_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.119.259341","volume":"371","author":"T Taniguchi","year":"2019","unstructured":"Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371:162\u201370. https:\/\/doi.org\/10.1124\/jpet.119.259341.","journal-title":"J Pharmacol Exp Ther"},{"key":"4844_CR11","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/DDDT.S416025","volume":"17","author":"K Yanai","year":"2023","unstructured":"Yanai K, Hirai K, Kaneko S, Mutsuyoshi Y, Kitano T, Miyazawa H, Ito K, Ueda Y, Ookawara S, Morishita Y. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: a single center, retrospective analysis. Drug Des Devel Ther. 2023;17:3233\u201348. https:\/\/doi.org\/10.2147\/DDDT.S416025.","journal-title":"Drug Des Devel Ther"},{"key":"4844_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10157-023-02419-w","volume":"28","author":"O Kurihara","year":"2024","unstructured":"Kurihara O, Yamada T, Kato K, Miyauchi Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin Exp Nephrol. 2024;28:208\u201316. https:\/\/doi.org\/10.1007\/s10157-023-02419-w.","journal-title":"Clin Exp Nephrol"},{"key":"4844_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-024-03535-9","volume":"25","author":"H Amano","year":"2024","unstructured":"Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol. 2024;25:97. https:\/\/doi.org\/10.1186\/s12882-024-03535-9.","journal-title":"BMC Nephrol"},{"key":"4844_CR14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of randomized controlled trials. J Am Soc Nephrol. 2019;30:1735\u201345. https:\/\/doi.org\/10.1681\/ASN.2019010007.","journal-title":"J Am Soc Nephrol"},{"key":"4844_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Change in albuminuria and GFR as end points for clinical trials in early CKD. Am J Kidney Dis. 2020;75:84\u2013104. https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.009.","journal-title":"Am J Kidney Dis"},{"key":"4844_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium\u2013glucose cotransporter 2 inhibitors. Kidney Int. 2018;94:26\u201339. https:\/\/doi.org\/10.1016\/j.kint.2017.12.027.","journal-title":"Kidney Int"},{"key":"4844_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"4844_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","volume":"49","author":"E Krishnan","year":"2007","unstructured":"Krishnan E, Kwoh CK, Schumacher HR, Kuller LH. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49:298\u2013303.","journal-title":"Hypertension"},{"key":"4844_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"4844_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Yokote K, Arai H, et al. Japan atherosclerosis society guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846\u2013984.","journal-title":"J Atheroscler Thromb"},{"key":"4844_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11:165\u2013223.","journal-title":"Diabetol Int"},{"key":"4844_CR22","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, Jennings C, Kotseva K, et al. Variation in secondary prevention of coronary heart disease: the INTERASPIRE study. Eur Heart J. 2024;45:4184\u201396.","journal-title":"Eur Heart J"},{"key":"4844_CR23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease: diagnosis and management. JAMA. 2019;322:1294\u2013304.","journal-title":"JAMA"},{"key":"4844_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963\u201374.","journal-title":"Biometrics"},{"key":"4844_CR25","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1159\/000345509","volume":"121","author":"LG S\u00e1nchez-Lozada","year":"2012","unstructured":"S\u00e1nchez-Lozada LG, Lanaspa MA, Crist\u00f3bal-Garc\u00eda M, Garc\u00eda-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ. Uric acid\u2013induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121:e71\u20138. https:\/\/doi.org\/10.1159\/000345509.","journal-title":"Nephron Exp Nephrol"},{"key":"4844_CR26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15257770802138558","volume":"27","author":"YY Sautin","year":"2008","unstructured":"Sautin YY, Johnson RJ. Uric acid: the oxidant\u2013antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27:608\u201319. https:\/\/doi.org\/10.1080\/15257770802138558.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"4844_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000342390","volume":"36","author":"M Kanbay","year":"2012","unstructured":"Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, Unal HU, Arslan E, Verim S, Madero M, Caglar K, Oguz Y, McFann K, Johnson RJ. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012;36:324\u201331. https:\/\/doi.org\/10.1159\/000342390.","journal-title":"Am J Nephrol"},{"key":"4844_CR28","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Ren Physiol. 2002;282:F991\u20137. https:\/\/doi.org\/10.1152\/ajprenal.00283.2001.","journal-title":"Am J Physiol Ren Physiol"},{"key":"4844_CR29","doi-asserted-by":"publisher","first-page":"11147","DOI":"10.1038\/s41598-018-29137-7","volume":"8","author":"T Takada","year":"2018","unstructured":"Takada T, Yamamoto T, Matsuo H, Tan JK, Ooyama K, Sakiyama M, et al. Identification of ABCG2 as an exporter of uremic toxin indoxyl sulfate in mice and as a crucial factor influencing CKD progression. Sci Rep. 2018;8:11147. https:\/\/doi.org\/10.1038\/s41598-018-29137-7.","journal-title":"Sci Rep"},{"key":"4844_CR30","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/sim.5686","volume":"32","author":"RM Daniel","year":"2013","unstructured":"Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JAC. Methods for dealing with time-dependent confounding. Stat Med. 2013;32:1584\u2013618. https:\/\/doi.org\/10.1002\/sim.5686.","journal-title":"Stat Med"},{"key":"4844_CR31","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/bmj.308.6942.1499","volume":"308","author":"JM Bland","year":"1994","unstructured":"Bland JM, Altman DG. Regression towards the mean. BMJ. 1994;308:1499. https:\/\/doi.org\/10.1136\/bmj.308.6942.1499.","journal-title":"BMJ"},{"key":"4844_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","volume":"16","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol. 2021;16:1278\u201380. https:\/\/doi.org\/10.2215\/CJN.02480221.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04844-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:32:30Z","timestamp":1774517550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04844-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4844"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04844-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nagoya City University Hospital (approval number: 60-25-0005) and conducted in accordance with the Declaration of Helsinki. Owing to the retrospective design, the requirement for written informed consent was waived. Study information was posted on the institutional website, and patients were given the opportunity to opt out. All data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}